Cargando…

The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber

OBJECTIVE: The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC in the artificial exposure chamber (OHIO chamber)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashiguchi, Kazuhiro, Okubo, Kimihiro, Wakabayashi, Ken-ichiro, Tanaka, Nobuaki, Watada, Yukiko, Suematsu, Kiyochika, Gotoh, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980728/
https://www.ncbi.nlm.nih.gov/pubmed/27536427
http://dx.doi.org/10.3109/21556660.2012.728547
_version_ 1782447505036804096
author Hashiguchi, Kazuhiro
Okubo, Kimihiro
Wakabayashi, Ken-ichiro
Tanaka, Nobuaki
Watada, Yukiko
Suematsu, Kiyochika
Gotoh, Minoru
author_facet Hashiguchi, Kazuhiro
Okubo, Kimihiro
Wakabayashi, Ken-ichiro
Tanaka, Nobuaki
Watada, Yukiko
Suematsu, Kiyochika
Gotoh, Minoru
author_sort Hashiguchi, Kazuhiro
collection PubMed
description OBJECTIVE: The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC in the artificial exposure chamber (OHIO chamber) would be optimal to start administration. METHODS: This was a single-institution, double-blind, randomized placebo-controlled four-group parallel inter-group comparison study. Adult volunteers with JC pollinosis were divided into four groups: an MLK 7-day administration group (n = 27), an MLK 3-day administration group (n = 27), an MLK 1-day administration group (n = 26), and a placebo group (n = 26). The mean change in total nasal symptom scores (nasal obstruction, nasal discharge and sneezing) (TNSS) and each of the nasal symptom scores during exposure of JC pollen in the OHIO chamber were investigated. RESULTS: The mean change in TNSS was significantly lower in the MLK treatment group, regardless of the number of days of administration, than in the placebo group (p = 0.0192). The results for the individual nasal symptoms showed that nasal obstruction was significantly suppressed in the 1-day administration group as compared with placebo (p = 0.0076), but no differences were found in sneezing score between any of the groups. For nasal discharge, we found a trend towards the effect clearing up after 3 days of administration. No serious adverse events were observed during the study. CONCLUSION: Although this study was acute and this artificial exposure model was conducted out of the pollen season, nasal symptoms that developed in the pollen exposure chamber, especially nasal obstruction, were significantly suppressed by starting oral administration of MLK 10 mg at least 1 day before exposure. These results suggest that prophylactic administration of MLK is effective and safe in the treatment of SAR.
format Online
Article
Text
id pubmed-4980728
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49807282016-08-17 The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber Hashiguchi, Kazuhiro Okubo, Kimihiro Wakabayashi, Ken-ichiro Tanaka, Nobuaki Watada, Yukiko Suematsu, Kiyochika Gotoh, Minoru J Drug Assess Original Articles OBJECTIVE: The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC in the artificial exposure chamber (OHIO chamber) would be optimal to start administration. METHODS: This was a single-institution, double-blind, randomized placebo-controlled four-group parallel inter-group comparison study. Adult volunteers with JC pollinosis were divided into four groups: an MLK 7-day administration group (n = 27), an MLK 3-day administration group (n = 27), an MLK 1-day administration group (n = 26), and a placebo group (n = 26). The mean change in total nasal symptom scores (nasal obstruction, nasal discharge and sneezing) (TNSS) and each of the nasal symptom scores during exposure of JC pollen in the OHIO chamber were investigated. RESULTS: The mean change in TNSS was significantly lower in the MLK treatment group, regardless of the number of days of administration, than in the placebo group (p = 0.0192). The results for the individual nasal symptoms showed that nasal obstruction was significantly suppressed in the 1-day administration group as compared with placebo (p = 0.0076), but no differences were found in sneezing score between any of the groups. For nasal discharge, we found a trend towards the effect clearing up after 3 days of administration. No serious adverse events were observed during the study. CONCLUSION: Although this study was acute and this artificial exposure model was conducted out of the pollen season, nasal symptoms that developed in the pollen exposure chamber, especially nasal obstruction, were significantly suppressed by starting oral administration of MLK 10 mg at least 1 day before exposure. These results suggest that prophylactic administration of MLK is effective and safe in the treatment of SAR. Taylor & Francis 2012-10-09 /pmc/articles/PMC4980728/ /pubmed/27536427 http://dx.doi.org/10.3109/21556660.2012.728547 Text en © 2012 The Author(s). Published by Taylor & Francis http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Original Articles
Hashiguchi, Kazuhiro
Okubo, Kimihiro
Wakabayashi, Ken-ichiro
Tanaka, Nobuaki
Watada, Yukiko
Suematsu, Kiyochika
Gotoh, Minoru
The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
title The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
title_full The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
title_fullStr The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
title_full_unstemmed The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
title_short The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
title_sort assessment of the optimal duration of early intervention with montelukast in the treatment of japanese cedar pollinosis symptoms induced in an artificial exposure chamber
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980728/
https://www.ncbi.nlm.nih.gov/pubmed/27536427
http://dx.doi.org/10.3109/21556660.2012.728547
work_keys_str_mv AT hashiguchikazuhiro theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT okubokimihiro theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT wakabayashikenichiro theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT tanakanobuaki theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT watadayukiko theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT suematsukiyochika theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT gotohminoru theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT hashiguchikazuhiro assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT okubokimihiro assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT wakabayashikenichiro assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT tanakanobuaki assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT watadayukiko assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT suematsukiyochika assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber
AT gotohminoru assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber